Question 1

Should I switch from Trulicity to Ozempic for better A1C control?

Accepted Answer

Often yes, if A1C is the main driver. SUSTAIN-7 (Pratley 2018 Lancet Diabetes Endocrinol, PMID 29397376) was the direct head-to-head: Ozempic 1 mg cut A1C 1.8% vs Trulicity 1.5 mg's 1.4%, and Ozempic 0.5 mg also beat Trulicity 0.75 mg. Weight loss was about twice as large with Ozempic. The trade-off is slightly more nausea and somewhat narrower coverage for some patient populations — ask your endocrinologist about a structured switch with 4 weeks at Ozempic 0.25 mg before stepping up.

Question 2

Why does my insurance prefer Trulicity over Ozempic?

Accepted Answer

Several reasons. Trulicity launched in 2014 and has long-standing PBM contracts — many commercial formularies still tier it preferred over Ozempic. REWIND (Gerstein 2019 Lancet, PMID 31189511) also gave Trulicity an FDA cardiovascular-risk-reduction indication that does not require established CVD, whereas Ozempic's SUSTAIN-6 indication is narrower. Insurers also factor in pediatric labeling (Trulicity is approved for ages 10+) and the AWARD-7 kidney-disease data when building step-therapy criteria. A formulary exception with documented A1C failure on Trulicity 1.5 mg is the usual path to Ozempic.

Question 3

Which is better for patients with kidney disease?

Accepted Answer

Trulicity has the stronger dedicated evidence in advanced CKD. AWARD-7 (Tuttle 2018 Lancet Diabetes Endocrinol, PMID 29910024) enrolled patients with stage 3-4 chronic kidney disease and showed dulaglutide produced A1C reductions non-inferior to insulin glargine with less eGFR decline over 52 weeks. Ozempic's program has reasonable CKD data in REFLECT/FLOW and reassuring renal-safety signals in SUSTAIN-6, but no head-to-head against insulin or against Trulicity in this population. For T2D patients with eGFR 15-60 ml/min/1.73 m², Trulicity has the cleaner labeled CKD story.

Question 4

Does Trulicity work for weight loss?

Accepted Answer

Modestly. Trulicity 1.5 mg typically produces 2-3 kg of weight loss in T2D trials — useful but well below semaglutide and tirzepatide. The higher Trulicity doses approved in 2020 (3 mg and 4.5 mg) push weight loss closer to 4-5 kg, but still not in the Ozempic range. Neither Trulicity nor Ozempic is FDA-approved for chronic weight management; that indication belongs to Wegovy (semaglutide 2.4 mg) and Zepbound (tirzepatide). Off-label use of Trulicity purely for weight loss in non-diabetic patients is rarely covered by insurance.

Question 5

Which is approved for kids with type 2 diabetes?

Accepted Answer

Trulicity. The FDA approved dulaglutide for pediatric patients aged 10 and older with type 2 diabetes in 2022, based on the AWARD-PEDS trial. Ozempic is not approved for pediatric use — its label is restricted to adults. For an adolescent with T2D who needs a once-weekly GLP-1, Trulicity is the labeled option; semaglutide is not. Wegovy (the obesity-indicated semaglutide brand) does have a pediatric label for chronic weight management in adolescents 12+, but Ozempic itself does not.

Question 6

Are the cardiovascular benefits the same?

Accepted Answer

No — they apply to different patient populations. SUSTAIN-6 (Marso 2016 NEJM, PMID 27633186) randomized 3,297 T2D patients at high CV risk and showed Ozempic cut major adverse cardiovascular events 26% (HR 0.74), but most participants had established cardiovascular disease. REWIND (Gerstein 2019 Lancet, PMID 31189511) randomized 9,901 T2D patients of whom only 31% had established CVD and showed Trulicity cut MACE 12% (HR 0.88) over a median 5.4 years. So Ozempic has the larger relative effect in secondary prevention; Trulicity has the only dedicated primary-prevention evidence base in T2D. Choose based on the patient's CV history.

Field	Ozempic	Trulicity
Mechanism	GLP-1 receptor agonist	GLP-1 receptor agonist
A1C reduction (SUSTAIN-7 head-to-head, 40 wk)	-1.8% (Ozempic 1 mg)	-1.4% (Trulicity 1.5 mg)
Weight loss (SUSTAIN-7 head-to-head, 40 wk)	-6.5 kg (Ozempic 1 mg)	-3.0 kg (Trulicity 1.5 mg)
FDA-approved indication	Type 2 diabetes; CV risk reduction in T2D + established CVD (adults only)	Type 2 diabetes (adults + pediatric ≥10); CV risk reduction in T2D ± CVD
Cardiovascular outcome trial	SUSTAIN-6: MACE -26% (HR 0.74, n=3,297, secondary-prevention bent)	REWIND: MACE -12% (HR 0.88, n=9,901, primary-prevention majority)
Advanced kidney disease (AWARD-7)	Not studied at this CKD stage in a dedicated head-to-head	A1C non-inferior to insulin glargine in stage 3-4 CKD; less eGFR decline
Dosing	Once-weekly subq; 0.25 → 0.5 → 1 → 2 mg	Once-weekly subq; 0.75 → 1.5 → 3 → 4.5 mg
Cash price (manufacturer programs)	~$998/mo retail; NovoCare savings card limited to commercially insured T2D patients	~$987/mo retail; Lilly $25 savings card for commercial insurance only

Ozempic vs Trulicity (2026): SUSTAIN-7 Head-to-Head, A1C, CV Outcomes

The verdict

Side-by-side comparison

Frequently asked questions